EE05715B1 - Antikehad insuliinitaolise kasvufaktori I retseptorile - Google Patents
Antikehad insuliinitaolise kasvufaktori I retseptorileInfo
- Publication number
- EE05715B1 EE05715B1 EEP200300318A EEP200300318A EE05715B1 EE 05715 B1 EE05715 B1 EE 05715B1 EE P200300318 A EEP200300318 A EE P200300318A EE P200300318 A EEP200300318 A EE P200300318A EE 05715 B1 EE05715 B1 EE 05715B1
- Authority
- EE
- Estonia
- Prior art keywords
- insulin
- antibodies
- receptor
- growth factor
- growth
- Prior art date
Links
- 102000038455 IGF Type 1 Receptor Human genes 0.000 title 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EEP201300037A EE05724B1 (et) | 2001-01-05 | 2001-12-20 | Antikehad insuliinitaolise kasvufaktori I retseptorile |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25992701P | 2001-01-05 | 2001-01-05 | |
PCT/US2001/051113 WO2002053596A2 (en) | 2001-01-05 | 2001-12-20 | Antibodies to insulin-like growth factor i receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200300318A EE200300318A (et) | 2003-10-15 |
EE05715B1 true EE05715B1 (et) | 2014-06-16 |
Family
ID=22987016
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP201300037A EE05724B1 (et) | 2001-01-05 | 2001-12-20 | Antikehad insuliinitaolise kasvufaktori I retseptorile |
EEP200300318A EE05715B1 (et) | 2001-01-05 | 2001-12-20 | Antikehad insuliinitaolise kasvufaktori I retseptorile |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP201300037A EE05724B1 (et) | 2001-01-05 | 2001-12-20 | Antikehad insuliinitaolise kasvufaktori I retseptorile |
Country Status (51)
Families Citing this family (294)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002053596A2 (en) | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
AU2013204100A1 (en) * | 2001-06-26 | 2013-05-09 | Amgen Fremont Inc. | Antibodies to OPGL |
DK2270052T3 (en) * | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
FR2834990A1 (fr) * | 2002-01-18 | 2003-07-25 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
FR2834900B1 (fr) * | 2002-01-18 | 2005-07-01 | Pf Medicament | Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications |
US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
AU2003216748B2 (en) * | 2002-01-18 | 2009-07-16 | Pierre Fabre Medicament | Novel anti-IGF-IR antibodies and uses thereof |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
FR2834991B1 (fr) * | 2002-01-18 | 2004-12-31 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
US6936427B2 (en) * | 2002-02-08 | 2005-08-30 | Trellis Bioscience, Inc. | Real time detection of intermolecular interaction |
AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
CA2484000A1 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
EP1551453A4 (de) * | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | Spezifitätsgrafting eines mäuseantikörpers auf ein menschliches gerüst |
AU2003275240A1 (en) * | 2002-09-24 | 2004-04-23 | Massachusetts Institute Of Technology | Methods and compositions for soluble cpg15 |
EP1596885A2 (de) * | 2003-02-13 | 2005-11-23 | Pfizer Products Inc. | Verwendungen von anti-insulin-ähnlichem wachstumsfaktor-i-rezeptor-antikörpern |
MXPA05009837A (es) * | 2003-03-14 | 2005-12-05 | Pharmacia Corp | Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres. |
WO2004087756A2 (en) * | 2003-04-02 | 2004-10-14 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
CN100378127C (zh) * | 2003-04-02 | 2008-04-02 | 霍夫曼-拉罗奇有限公司 | 针对胰岛素样生长因子i受体的抗体及其应用 |
US7310537B2 (en) * | 2003-04-25 | 2007-12-18 | Nokia Corporation | Communication on multiple beams between stations |
JP2007535895A (ja) * | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体 |
ATE458006T1 (de) * | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
JP4638870B2 (ja) * | 2003-08-13 | 2011-02-23 | ファイザー・プロダクツ・インク | 修飾ヒトigf−1r抗体 |
WO2005028515A1 (ja) * | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
US20050187175A1 (en) * | 2003-09-30 | 2005-08-25 | Elly Nedivi | Methods and compositions for CPG15-2 |
US9011880B2 (en) * | 2003-10-21 | 2015-04-21 | Igf Oncology, Llc | Compounds and methods for treating cancer |
EP1694850B1 (de) | 2003-11-12 | 2011-06-29 | Schering Corporation | Plasmidsystem zur expression mehrerer gene |
PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
MXPA06005540A (es) * | 2003-12-08 | 2006-08-17 | Immunogen Inc | Anticuerpo del receptor anti-igf-i. |
AU2005249396B2 (en) * | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
EP1802341A1 (de) * | 2004-07-16 | 2007-07-04 | Pfizer Products Inc. | Kombinationsbehandlung für nicht-hämatologische bösartige erkrankungen mit einem anti-igf-1r-antikörper |
FR2873699B1 (fr) * | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
KR20080003390A (ko) | 2005-03-31 | 2008-01-07 | 어젠시스 인코포레이티드 | 161p2f10b 단백질과 결합하는 항체 및 관련 분자 |
AU2006236637B2 (en) * | 2005-04-15 | 2012-09-06 | Merck Sharp & Dohme Corp. | Methods and compositions for treating or preventing cancer |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
MX2007015476A (es) * | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
KR20080019249A (ko) * | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
EP2505205A1 (de) * | 2005-06-17 | 2012-10-03 | Imclone LLC | Anti-PDGFR-alpha-Antikörper |
WO2007000328A1 (en) * | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
TWI453218B (zh) | 2005-09-07 | 2014-09-21 | Amgen Fremont Inc | 針對類活化素受體激酶-1之人類單株抗體 |
CN100445300C (zh) * | 2005-09-30 | 2008-12-24 | 李玉新 | Glp-1融合蛋白及其制备方法和医药用途 |
JP2009516513A (ja) | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
RS52357B (en) | 2005-12-13 | 2012-12-31 | Medimmune Limited | BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE |
AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
EP2671954B1 (de) | 2006-01-20 | 2018-05-16 | Cell Signaling Technology, Inc. | Translokation und Mutations-ROS-Kinase bei menschlichem nicht-kleinzelligem Lungenkrebs |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
CA2641310C (en) | 2006-02-03 | 2013-08-20 | Imclone Systems Incorporated | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
US7884078B2 (en) * | 2006-02-10 | 2011-02-08 | Massachusetts Institute Of Technology | CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists |
EP1999149A4 (de) | 2006-03-28 | 2010-01-20 | Biogen Idec Inc | Anti-igf-ir-antikörper und ihre verwendung |
CA2647111A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
EP2447360A1 (de) | 2006-04-14 | 2012-05-02 | Cell Signaling Technology, Inc. | Gendefekte und Mutante ALK-Kinase in festen menschlichen Tumoren |
MX2008013990A (es) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
WO2008005469A2 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Igfbp2 biomarker |
CA2672828A1 (en) | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of treatment |
WO2008079849A2 (en) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
EA200900991A1 (ru) * | 2007-02-14 | 2010-02-26 | Глаксо Груп Лимитед | Новые антитела против igf-1r |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
WO2008104344A1 (en) * | 2007-02-27 | 2008-09-04 | F. Hoffmann-La Roche Ag | Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor |
ES2707551T3 (es) * | 2007-03-02 | 2019-04-04 | Amgen Inc | Métodos y composiciones para tratar enfermedades tumorales |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
ES2529790T3 (es) | 2007-04-13 | 2015-02-25 | Dana-Farber Cancer Institute, Inc. | Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB |
EP2559771A3 (de) | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarker und Verfahren zur Bestimmung der Empfindlichkeit gegen Rezeptor-1-Modulatoren des vaskulären Insulinwachstumsfaktors |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
US20090130105A1 (en) * | 2007-08-28 | 2009-05-21 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
AU2008295506A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-IGF-1R antibodies and uses thereof |
JP5570989B2 (ja) * | 2007-08-31 | 2014-08-13 | アムジエン・インコーポレーテツド | 固体タンパク質製剤 |
AU2008304111B2 (en) * | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
EP3741851A1 (de) | 2007-10-18 | 2020-11-25 | Cell Signaling Technology, Inc. | Translokation und mutante ros-kinase in humanem nichtkleinzelligem lungenkarzinom |
EP3381445B1 (de) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Wässrige antikörperformulierung mit stabilisierung durch antioxidantien zur parenteralen verabreichung |
DK2851374T3 (en) | 2007-12-14 | 2017-06-19 | Bristol Myers Squibb Co | Binding molecules to the human OX40 receptor |
US20100261216A1 (en) | 2007-12-21 | 2010-10-14 | Bianca Eser | Stability testing of antibodies |
WO2009142810A2 (en) * | 2008-03-25 | 2009-11-26 | Schering Corporation | Methods for treating or preventing colorectal cancer |
CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
KR20110016958A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
EP2328890B1 (de) | 2008-08-06 | 2012-01-25 | Pfizer Inc. | 6-substituierte 2-heterocyclylaminopyrazinverbindungen als chk-1-inhibitoren |
PT2376116E (pt) | 2008-12-12 | 2016-02-24 | Boehringer Ingelheim Int | Anticorpos anti-igf |
PL2881402T3 (pl) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
CN102448494B (zh) | 2009-02-13 | 2016-02-03 | 免疫医疗公司 | 具有胞内可裂解的键的免疫共轭物 |
EP2236139A1 (de) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Kombinationstherapie aus Erlotinib mit einem Anti-IGF-1R-Antikörper, der die Bindung von Insulin an den Insulinrezeptor nicht hemmt |
AR075982A1 (es) | 2009-03-31 | 2011-05-11 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion |
US8852590B2 (en) | 2009-04-16 | 2014-10-07 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
CN102753578B (zh) * | 2009-04-27 | 2015-04-22 | 诺华股份有限公司 | 增加肌肉生长的组合物和方法 |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
EP2421357B1 (de) | 2009-07-08 | 2013-01-23 | Kymab Limited | Tiermodelle und therapeutische moleküle |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
IN2012DN01663A (de) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
WO2011050333A1 (en) | 2009-10-23 | 2011-04-28 | Amgen Inc. | Vial adapter and system |
KR101436219B1 (ko) | 2009-10-26 | 2014-09-01 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US20120220594A1 (en) | 2009-10-30 | 2012-08-30 | Bristol-Meyers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
RU2724663C2 (ru) | 2010-02-08 | 2020-06-25 | Ридженерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
WO2011156373A1 (en) | 2010-06-07 | 2011-12-15 | Amgen Inc. | Drug delivery device |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
BR112013000951A2 (pt) | 2010-07-12 | 2016-05-17 | Covx Technologies Ireland Ltd | conjungados de anticorpo multifuncionais |
MX341579B (es) | 2010-08-03 | 2016-08-25 | Abbvie Inc * | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
TW201211252A (en) | 2010-08-26 | 2012-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
NZ714128A (en) | 2010-09-09 | 2017-10-27 | Pfizer | 4-1bb binding molecules |
SG189104A1 (en) * | 2010-09-28 | 2013-05-31 | Nono Inc | Nd2 peptides and methods of treating neurological disease |
EP3974453A3 (de) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
WO2012071557A1 (en) | 2010-11-24 | 2012-05-31 | Litron Laboratories, Ltd | Rapid in vivo gene mutation assay based on the pig-a gene |
MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
RU2013139267A (ru) | 2011-02-10 | 2015-03-20 | Рош Гликарт Аг | Улучшенная иммунотерапия |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
DK3138581T3 (en) | 2011-03-17 | 2019-04-15 | Univ Birmingham | REDIRECTED IMMUNTERY |
MX339927B (es) | 2011-03-29 | 2016-06-16 | Immunogen Inc | Preparacion de conjugados de maitansinoides y anticuerpos mediante un proceso de una etapa. |
SG193996A1 (en) | 2011-03-29 | 2013-11-29 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
CN103703026B (zh) * | 2011-04-19 | 2015-08-26 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
CA2830972C (en) | 2011-04-19 | 2018-11-20 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
EP2699293B8 (de) | 2011-04-20 | 2022-07-20 | Amgen Inc. | Autoinjektorvorrichtung |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
SI2739740T1 (sl) | 2011-08-05 | 2019-12-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane univerzalne lahkoverižne miši |
AU2012300279A1 (en) | 2011-08-26 | 2014-04-03 | Merrimack Pharmaceuticals, Inc. | Tandem Fc bispecific antibodies |
AU2012311286B2 (en) * | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
EP2761008A1 (de) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimäre surrogatleichtketten (slc) mit humanem vpreb |
WO2013056069A1 (en) | 2011-10-13 | 2013-04-18 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
US9987428B2 (en) | 2011-10-14 | 2018-06-05 | Amgen Inc. | Injector and method of assembly |
US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
KR101470700B1 (ko) * | 2011-11-25 | 2014-12-12 | 서울대학교산학협력단 | 표적 항암제의 내성 극복 방법 |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
US9997847B2 (en) | 2011-12-27 | 2018-06-12 | Perfectvision Manufacturing, Inc. | Coaxial Connector with grommet biasing for enhanced continuity |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
EP2631653A1 (de) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identifizierung von Modulatoren der Bindungseigenschaften von mit einem Mitglied der Insulinrezeptorfamilie reaktiven Antikörpern |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
WO2013158859A1 (en) | 2012-04-18 | 2013-10-24 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
KR20200075023A (ko) | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
CA2875543A1 (en) | 2012-06-21 | 2013-12-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
EP3539563A1 (de) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Für cd22 spezifischer antikörper und verfahren zur verwendung davon |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
PL3434695T3 (pl) | 2012-08-07 | 2021-05-17 | Roche Glycart Ag | Ulepszona immunoterapia |
EP2885002A4 (de) | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten |
WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
WO2014081780A1 (en) | 2012-11-21 | 2014-05-30 | Amgen Inc. | Drug delivery device |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
KR102196374B1 (ko) | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 길항제 |
LT2900277T (lt) | 2012-12-13 | 2022-04-11 | Immunomedics, Inc. | Antikūnų ir sn-38 imunokonjugatų dozės, skirtos pagerintam veiksmingumui ir sumažintam toksiškumui |
BR112015021462A2 (pt) | 2013-03-06 | 2017-10-10 | Adimab Llc | anticorpos biespecíficos anti-c-met tandem fc |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
TW201512219A (zh) | 2013-03-15 | 2015-04-01 | Abbvie Inc | 針對IL-1β及/或IL-17之雙特異性結合蛋白 |
US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
EP2968760B1 (de) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Medikamentenkassette, autoinjektor und autoinjektorsystem |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
WO2014149357A1 (en) | 2013-03-22 | 2014-09-25 | Amgen Inc. | Injector and method of assembly |
CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
ES2862125T3 (es) * | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Terapia combinada para acromegalia |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
US11427627B2 (en) | 2013-09-05 | 2022-08-30 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
TW201546284A (zh) | 2013-10-01 | 2015-12-16 | Kymab Ltd | 動物模式及治療分子 |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
EP3957345A1 (de) | 2013-10-24 | 2022-02-23 | Amgen, Inc | Arzneimittelabgabesystem mit temperaturempfindlicher steuerung |
WO2015106224A2 (en) | 2014-01-12 | 2015-07-16 | Hugh Mctavish | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3107577B1 (de) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
SG11201609219QA (en) | 2014-05-07 | 2016-12-29 | Amgen Inc | Autoinjector with shock reducing elements |
AU2015259053B2 (en) | 2014-05-16 | 2020-12-24 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
US10646652B2 (en) | 2014-06-03 | 2020-05-12 | Amgen Inc. | Controllable drug delivery system and method of use |
WO2015200260A1 (en) | 2014-06-24 | 2015-12-30 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
CA2961774C (en) | 2014-10-07 | 2023-05-23 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
JP6730271B2 (ja) | 2014-10-29 | 2020-07-29 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | インターフェロンα2Bバリアント |
CN107592813A (zh) | 2014-11-19 | 2018-01-16 | 伊缪诺金公司 | 用于制备细胞结合剂‑细胞毒性剂缀合物的方法 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (ja) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | 近接センサ付き薬物送達装置 |
MX2017010466A (es) | 2015-02-17 | 2018-06-06 | Amgen Inc | Dispositivo de administracion de farmacos con sujecion asistida de vacio y/o respuestas. |
AU2016219772A1 (en) * | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
WO2016138434A1 (en) | 2015-02-27 | 2016-09-01 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CA2983597A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3316885B1 (de) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antikörper-sn-38-immunkonjugate mit einem cl2a-linker |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017136623A1 (en) | 2016-02-05 | 2017-08-10 | Immunogen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
JP6987072B2 (ja) | 2016-03-10 | 2021-12-22 | アクセレロン ファーマ インコーポレーテッド | アクチビン2型受容体結合タンパク質及びその使用 |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (de) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
EP3532127A1 (de) | 2016-10-25 | 2019-09-04 | Amgen Inc. | Injektor am körper |
CN108084262A (zh) * | 2016-11-23 | 2018-05-29 | 复旦大学 | 针对寨卡病毒的全人源单域抗体或抗原结合片段及应用 |
CN110494445B (zh) | 2017-01-06 | 2023-10-20 | Abl生物公司 | 抗α-SYN抗体及其用途 |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
AU2018220538B2 (en) | 2017-02-17 | 2023-12-14 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
JP2020508803A (ja) | 2017-03-06 | 2020-03-26 | アムジエン・インコーポレーテツド | 作動防止特徴部を備える薬物送達デバイス |
EP3592402A1 (de) | 2017-03-07 | 2020-01-15 | Amgen Inc. | Nadeleinführung durch überdruck |
IL303449B2 (en) | 2017-03-09 | 2024-08-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
US20200131518A1 (en) | 2017-03-14 | 2020-04-30 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
SI3600491T1 (sl) | 2017-03-28 | 2023-11-30 | Amgen Inc. | Sistem in postopek za sestavljanja droga bata in brizge |
CA3059593A1 (en) | 2017-05-21 | 2018-11-29 | Igf Oncology, Llc | An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
EP3641857A1 (de) | 2017-06-22 | 2020-04-29 | Amgen Inc. | Aufprall-/stossdämpfungsminderung bei geräteaktivierung |
MX2019015479A (es) | 2017-06-23 | 2020-02-20 | Amgen Inc | Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador. |
JP7408398B2 (ja) | 2017-07-14 | 2024-01-05 | アムジエン・インコーポレーテツド | 二重ねじりばねシステムを有する針挿入後退システム |
EP3655063A1 (de) | 2017-07-21 | 2020-05-27 | Amgen Inc. | Gasdurchlässiges dichtelement für arzneimittelbehälter und verfahren zur montage |
EP3658206A1 (de) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Arzneimittelabgabevorrichtung mit behälterzugangssystem und zugehörigem verfahren zur montage |
WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
US20210332141A1 (en) | 2017-08-30 | 2021-10-28 | Amgen Inc. | Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use |
ES2939292T3 (es) | 2017-10-04 | 2023-04-20 | Amgen Inc | Adaptador de flujo para dispositivo de administración de fármacos |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD |
IL273323B1 (en) | 2017-10-09 | 2024-06-01 | Amgen Inc | Drug delivery device with drive assembly and related assembly method |
AU2018354418A1 (en) * | 2017-10-27 | 2020-05-14 | Immunebridge Inc. | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene |
EP3703779A1 (de) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systeme und ansätze zur sterilisation einer arzneimittelabgabevorrichtung |
US12053618B2 (en) | 2017-11-06 | 2024-08-06 | Amgen Inc. | Fill-finish assemblies and related methods |
US20200261648A1 (en) | 2017-11-06 | 2020-08-20 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3706826A1 (de) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Kolben für wirkstofffreisetzungsvorrichtungen |
CA3084486A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
US20210228815A1 (en) | 2018-07-24 | 2021-07-29 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CA3110529A1 (en) | 2018-10-02 | 2020-04-09 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
AU2019355979A1 (en) | 2018-10-05 | 2021-03-18 | Amgen Inc. | Drug delivery device having dose indicator |
CA3112355A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
EP3873563A1 (de) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Vorrichtung zur verabreichung von medikamenten mit partiellem einzug des wirkstoffabgabeelements |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
MX2021006495A (es) * | 2018-12-03 | 2021-07-06 | Teijin Pharma Ltd | Anticuerpo humanizado del receptor anti-igf-i. |
US11464786B2 (en) | 2018-12-12 | 2022-10-11 | Chemocentryx, Inc. | CXCR7 inhibitors for the treatment of cancer |
WO2020131697A2 (en) | 2018-12-17 | 2020-06-25 | Revitope Limited | Twin immune cell engager |
AU2020263289A1 (en) | 2019-04-24 | 2021-09-16 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
US20220349898A1 (en) | 2019-09-26 | 2022-11-03 | Amgen Inc. | Methods of producing antibody compositions |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
JP2024503933A (ja) | 2021-01-27 | 2024-01-29 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Cd16aに対する単一ドメイン抗体およびその使用 |
WO2022192281A1 (en) * | 2021-03-08 | 2022-09-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | MOLECULES THAT BIND TO CD66e POLYPEPTIDES |
CN112794912B (zh) * | 2021-04-14 | 2021-07-06 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
JPWO2022239720A1 (de) | 2021-05-10 | 2022-11-17 | ||
US20240208680A1 (en) | 2021-05-21 | 2024-06-27 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
EP4352094A1 (de) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Verwendung von fucosidase zur steuerung des afucosylierungsniveaus glykosylierter proteine |
CA3233279A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023143484A1 (zh) * | 2022-01-29 | 2023-08-03 | 明慧医药(杭州)有限公司 | 一种抗原结合蛋白及其用途 |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
CN117079823B (zh) * | 2023-10-17 | 2024-01-02 | 北京大学第三医院(北京大学第三临床医学院) | 早期预测选择性胎儿生长受限发病风险筛查的系统和方法 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US586510A (en) * | 1897-07-13 | Coal-grading machine | ||
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US4968516A (en) * | 1989-07-24 | 1990-11-06 | Thompson Neal W | Method and apparatus for cooking foodstuffs using auxiliary steam |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1996033735A1 (en) * | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (de) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2090473A1 (en) | 1990-08-29 | 1992-03-01 | Robert M. Kay | Homologous recombinatin in mammalian cells |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
ES2287206T3 (es) | 1991-03-01 | 2007-12-16 | Dyax Corporation | Proceso para el desarrollo de mini-proteinas de union. |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
AU658187B2 (en) | 1991-04-19 | 1995-04-06 | Boehringer Mannheim Gmbh | Human bone derived insulin like growth factor binding protein |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
WO1994019935A1 (en) | 1993-03-09 | 1994-09-15 | Genzyme Corporation | Isolation of components of interest from milk |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
IT1270882B (it) * | 1993-10-05 | 1997-05-13 | Isagro Srl | Oligopeptidi ad attivita' fungicida |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
JPH08140528A (ja) | 1993-12-03 | 1996-06-04 | Genpharm Internatl Inc | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
ATE198326T1 (de) | 1995-04-20 | 2001-01-15 | Pfizer | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
EP0861267A4 (de) * | 1995-11-14 | 2000-02-02 | Univ Jefferson | Induktion und resistenz gegen tumorwachstum mittels loeslichem igf-1 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
IL118626A0 (en) | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibody |
EP0818442A3 (de) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
PL331154A1 (en) | 1996-07-13 | 1999-06-21 | Glaxo Group Ltd | Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
CZ11899A3 (cs) | 1996-07-18 | 1999-11-17 | Pfizer Inc. | Fosfinátové sloučeniny, farmaceutické prostředky, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení |
US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
BR9714266A (pt) | 1997-01-06 | 2000-04-18 | Pfizer | Derivados de sulfona cìclicos. |
BR9807815A (pt) | 1997-02-03 | 2000-03-08 | Pfizer Prod Inc | Derivados de ácido arilsulfonilamino-hidroxâmico |
JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
SK101399A3 (en) | 1997-02-11 | 2001-09-11 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2239393T3 (es) | 1997-05-07 | 2005-09-16 | Sugen, Inc. | Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa. |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
TR200000368T2 (tr) | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
CA2303830A1 (en) | 1997-09-26 | 1999-04-08 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
CA2322749A1 (en) | 1998-03-03 | 1999-09-10 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
NZ508815A (en) | 1998-05-29 | 2005-02-25 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US7173005B2 (en) * | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
ATE260255T1 (de) | 1998-11-05 | 2004-03-15 | Pfizer Prod Inc | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate |
JP3793693B2 (ja) | 1998-12-23 | 2006-07-05 | ファイザー インコーポレーテッド | Ctla−4に対するヒトモノクローナル抗体 |
AU3579200A (en) | 1999-02-26 | 2000-09-14 | Saltech I Goteborg Ab | Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 |
CZ303725B6 (cs) | 1999-03-25 | 2013-04-03 | Abbott Gmbh & Co. Kg | Lidské protilátky, které se vází na lidský IL-12 a zpusoby jejich produkce |
JP4224894B2 (ja) * | 1999-06-04 | 2009-02-18 | チッソ株式会社 | 複合強化ポリオレフィン樹脂組成物の製造方法及びその製造装置 |
US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
WO2002053596A2 (en) | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
JP2007535895A (ja) | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体 |
JP4638870B2 (ja) | 2003-08-13 | 2011-02-23 | ファイザー・プロダクツ・インク | 修飾ヒトigf−1r抗体 |
MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
US10181126B2 (en) | 2012-03-13 | 2019-01-15 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
-
2001
- 2001-12-20 WO PCT/US2001/051113 patent/WO2002053596A2/en active Application Filing
- 2001-12-20 CA CA2433800A patent/CA2433800C/en not_active Expired - Fee Related
- 2001-12-20 PA PA20018535501A patent/PA8535501A1/es unknown
- 2001-12-20 MX MXPA03006034A patent/MX337162B/es active IP Right Grant
- 2001-12-20 UA UA2003087419A patent/UA87804C2/ru unknown
- 2001-12-20 PL PL413188A patent/PL228041B1/pl unknown
- 2001-12-20 PE PE2001001290A patent/PE20020801A1/es active IP Right Grant
- 2001-12-20 EP EP01991634A patent/EP1399483B1/de not_active Expired - Lifetime
- 2001-12-20 ES ES01991634T patent/ES2344592T3/es not_active Expired - Lifetime
- 2001-12-20 NZ NZ527302A patent/NZ527302A/en not_active IP Right Cessation
- 2001-12-20 GE GE5278A patent/GEP20084484B/en unknown
- 2001-12-20 CZ CZ20032131A patent/CZ301712B6/cs not_active IP Right Cessation
- 2001-12-20 SK SK993-2003A patent/SK287954B6/sk not_active IP Right Cessation
- 2001-12-20 HN HN2001000283A patent/HN2001000283A/es unknown
- 2001-12-20 PL PL366340A patent/PL217921B1/pl unknown
- 2001-12-20 BR BR0116728-6A patent/BR0116728A/pt not_active IP Right Cessation
- 2001-12-20 MY MYPI20015796A patent/MY143465A/en unknown
- 2001-12-20 DK DK01991634.5T patent/DK1399483T3/da active
- 2001-12-20 PL PL407889A patent/PL224873B1/pl unknown
- 2001-12-20 EP EP20100177965 patent/EP2275446A3/de not_active Withdrawn
- 2001-12-20 EA EA200300766A patent/EA012079B3/ru not_active IP Right Cessation
- 2001-12-20 BR BRPI0116728A patent/BRPI0116728B1/pt unknown
- 2001-12-20 MX MX2014005206A patent/MX349009B/es unknown
- 2001-12-20 JP JP2002555118A patent/JP2004531217A/ja not_active Withdrawn
- 2001-12-20 OA OA1200300167A patent/OA12589A/en unknown
- 2001-12-20 AT AT01991634T patent/ATE464322T1/de active
- 2001-12-20 DZ DZ013494A patent/DZ3494A1/fr active
- 2001-12-20 KR KR1020037009063A patent/KR100830082B1/ko not_active IP Right Cessation
- 2001-12-20 EP EP10157999.3A patent/EP2194067B1/de not_active Expired - Lifetime
- 2001-12-20 CN CN2006100597041A patent/CN1854157B/zh not_active Expired - Fee Related
- 2001-12-20 SV SV2001000775A patent/SV2007000775A/es unknown
- 2001-12-20 EE EEP201300037A patent/EE05724B1/et not_active IP Right Cessation
- 2001-12-20 RS YUP-542/03A patent/RS51373B/sr unknown
- 2001-12-20 HU HU0302525A patent/HUP0302525A2/hu unknown
- 2001-12-20 UY UY27087A patent/UY27087A1/es not_active Application Discontinuation
- 2001-12-20 DE DE60141855T patent/DE60141855D1/de not_active Expired - Lifetime
- 2001-12-20 MA MA26448A patent/MA26040A1/fr unknown
- 2001-12-20 EP EP14173550.6A patent/EP2796468A2/de not_active Withdrawn
- 2001-12-20 IL IL15666101A patent/IL156661A0/xx active IP Right Grant
- 2001-12-20 EE EEP200300318A patent/EE05715B1/xx not_active IP Right Cessation
- 2001-12-20 AP APAP/P/2001/002365A patent/AP2072A/en active
- 2001-12-20 SG SG200506384-7A patent/SG138469A1/en unknown
- 2001-12-20 ME MEP-2008-813A patent/ME00502B/me unknown
- 2001-12-20 CN CNB018218083A patent/CN1330668C/zh not_active Expired - Fee Related
- 2001-12-20 AR ARP010105964A patent/AR032028A1/es not_active Application Discontinuation
- 2001-12-20 NZ NZ569856A patent/NZ569856A/en not_active IP Right Cessation
- 2001-12-20 AU AU2002231368A patent/AU2002231368C1/en not_active Ceased
- 2001-12-20 PT PT01991634T patent/PT1399483E/pt unknown
- 2001-12-20 TN TNTNSN01177A patent/TNSN01177A1/fr unknown
- 2001-12-20 ZA ZA200305995A patent/ZA200305995B/en unknown
- 2001-12-28 GT GT200100257A patent/GT200100257A/es unknown
-
2002
- 2002-01-04 TW TW091100073A patent/TWI324609B/zh not_active IP Right Cessation
- 2002-01-04 US US10/038,591 patent/US7037498B2/en not_active Expired - Lifetime
-
2003
- 2003-06-26 IL IL156661A patent/IL156661A/en not_active IP Right Cessation
- 2003-07-04 NO NO20033074A patent/NO339789B1/no not_active IP Right Cessation
- 2003-07-04 IS IS6866A patent/IS2790B/is unknown
- 2003-07-28 BG BG108037A patent/BG66460B1/bg unknown
- 2003-08-01 EC EC2003004711A patent/ECSP034711A/es unknown
- 2003-08-04 HR HR20030627A patent/HRP20030627A2/hr not_active Application Discontinuation
- 2003-08-05 CR CR7045A patent/CR7045A/es unknown
- 2003-12-20 CU CU20030148A patent/CU23447B7/es unknown
-
2005
- 2005-06-02 US US11/144,248 patent/US7815907B2/en not_active Expired - Fee Related
- 2005-06-02 US US11/144,222 patent/US7700742B2/en not_active Expired - Fee Related
- 2005-06-08 HK HK05104844A patent/HK1072059A1/xx not_active IP Right Cessation
-
2007
- 2007-04-24 HK HK07104264.4A patent/HK1098162A1/xx not_active IP Right Cessation
-
2008
- 2008-07-08 CR CR10134A patent/CR10134A/es unknown
- 2008-10-16 JP JP2008267173A patent/JP4456166B2/ja not_active Expired - Fee Related
-
2009
- 2009-05-08 CR CR10786A patent/CR10786A/es unknown
- 2009-09-28 JP JP2009222178A patent/JP5697862B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-08 US US12/756,417 patent/US7982024B2/en not_active Expired - Fee Related
-
2011
- 2011-06-27 US US13/169,474 patent/US8642037B2/en not_active Expired - Fee Related
-
2013
- 2013-07-10 HR HRP20130659AA patent/HRP20130659A2/hr not_active Application Discontinuation
- 2013-12-13 BG BG10111652A patent/BG111652A/en unknown
- 2013-12-19 US US14/135,026 patent/US9234041B2/en not_active Expired - Fee Related
-
2014
- 2014-01-06 CR CR20140001A patent/CR20140001A/es unknown
- 2014-12-05 JP JP2014246399A patent/JP6166243B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-09 UY UY0001035948A patent/UY35948A/es not_active Application Discontinuation
- 2015-04-24 HK HK15104006.7A patent/HK1203521A1/xx unknown
- 2015-12-17 US US14/973,498 patent/US20160096894A1/en not_active Abandoned
-
2016
- 2016-01-13 BG BG112197A patent/BG112197A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200300318A (et) | Antikehad insuliinitaolise kasvufaktori I retseptorile | |
DK1646720T3 (da) | Antistoffer mod insulinlignende vækstfaktor I-receptor og anvendelser deraf | |
EE200300509A (et) | Antikehad VLA-1 vastu | |
EP1572874A3 (de) | An trail-rezeptoren immunspezifisch bindende antikörper | |
EP1465925A4 (de) | "antikörper, die sich immunspezifisch an trail?rezeptoren binden" | |
HK1075470A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
DK1501856T3 (da) | Anti-HER2 antistofvarianter | |
NO20042182L (no) | Kjemisk-modifiserte veksthormonkonjugater | |
CY2012003I1 (el) | Αντισωματα που συνδεονται ανοσοειδικως προς blys | |
ATE286730T1 (de) | Kristalline zusammensetzung mit escitalopram | |
DK1524272T3 (da) | Væksthormonsekretionsfremmere | |
DK1333853T3 (da) | Vækstfaktorkompleks | |
EE200300569A (et) | CD44v6-spetsiifilised antikehad | |
AU2002352676A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
AU2001297702A1 (en) | Antibodies that immunospecifically bind to trail receptors | |
TH0101005173A (th) | แอนติบอดี้ต่อโกรทแฟคเตอร์ i รีเซฟเตอร์ที่เหมือนอินซูลิน | |
FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
EE200300377A (et) | Loomulikud HI-viiruse vastased antikehad | |
DK1494693T3 (da) | Cripto-specifikke antistoffer | |
DE60239895D1 (de) | Humanisierte super-antikörper | |
AU2004901994A0 (en) | Antibodies to insulin-like growth factor I receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
HK1A | Erratum in gazette | ||
MM4A | Lapsed by not paying the annual fees |
Effective date: 20191220 |